Polylysine-Coated Iron Oxide Nanoparticles for Cold Tumor Immunotherapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapy methods, such as immune checkpoint blockade (ICB) therapies, are ineffective for patients with 'cold' tumors due to low neo-antigen load and limited immune cell infiltration, and radiation therapy (RT) can activate detrimental immune suppressive effects, such as M2 macrophage recruitment, diminishing treatment efficacy.

Innovation Solution

Development of positively charged polymer-coated iron oxide nanoparticles (PIC NPs) that sensitize tumor cells to RT, facilitate antigen presentation, stimulate type I interferon responses, and increase M1 macrophage infiltration, thereby enhancing the immune response against tumors, including 'cold' ones, by combining with RT and checkpoint inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If radiation therapy is used to treat tumors, then tumor cell death is achieved, but immune suppressive effects are activated leading to M2 macrophage recruitment and reduced treatment efficacy

Engineering Contradiction:

Improvetreatment efficacyVSAvoidimmune suppressive effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful immune suppressive effects of radiation therapy into beneficial immune activating effects by using the same radiation-induced cellular stress pathways to trigger type I interferon responses and M1 macrophage polarization, thereby transforming radiation's detrimental immunosuppression into therapeutic immunostimulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the immunological parameters of the tumor microenvironment by modulating macrophage polarization states from M2 (suppressive) to M1 (anti-tumor) phenotype, and by altering cytokine profiles to enhance type I interferon signaling, thereby converting the immunosuppressive radiation environment into an immunologically active one

Inventive Principle:

Principle #35Parameter changes

2Reliability

If ICB therapy is administered to patients with cold tumors, then immune checkpoint blockade is achieved, but response rates remain low due to low neo-antigen load and limited immune cell infiltration

Engineering Contradiction:

Improveresponse rateVSAvoidimmune cell infiltration

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by using radiation therapy and type I interferon induction before ICB therapy to pre-condition the tumor microenvironment, increasing neo-antigen load and promoting immune cell infiltration, thereby preparing the 'cold' tumor to respond to subsequent checkpoint blockade treatment

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent introduces type I interferon as an intermediary substance that mediates between radiation therapy and the immune system, facilitating antigen presentation and T cell activation, thereby bridging the gap between radiation-induced cell death and effective immune recognition in cold tumors

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If M2 macrophages predominate in the tumor microenvironment, then immunosuppressive microenvironment is created, but anti-tumor immune response is diminished

Engineering Contradiction:

Improveanti-tumor immune responseVSAvoidimmunosuppressive microenvironment

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies inversion by reversing the macrophage polarization paradigm—instead of accepting M2 predominance as a given, it actively induces M1 polarization and suppresses M2 differentiation through type I interferon signaling, thereby inverting the immunosuppressive microenvironment into an immunologically active one that supports anti-tumor immunity

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The PIC NPs potentiate the in situ vaccination effect of RT, improving the response to ICB therapy by increasing tumor-specific T cell responses and converting 'cold' tumors into 'hot' microenvironments, leading to enhanced anti-tumor immunity and treatment efficacy.

Implementation Method 1

a positively charged polymer having a plurality of positive charges (e.g., polylysine (PLL)) electrostatically bound to iron oxide nanoparticles (ION) and CpG oligodeoxynucleotide

Methodology Applied

Scientific EffectElectrostatic binding: Electrostatics

Data Source

PatentUS20250009918A1Nanoparticles for potentiating effects of radiation therapy on Anti-cancer immunotherapy

Publication Date: 2025.01.09 WISCONSIN ALUMNI RES FOUND

AI summary

The present technology provides nanoparticles comprising a positively charged polymer (e.g., polylysine) electrostatically bound to iron oxide nanoparticles and CpG oligodeoxy nucleotide. Further provided are compositions comprising same and methods of sensitizing tumor cells to radiation therapy, methods of stimulating antigen presenting cells, methods of enhancing stimulation of a type I interferon, and methods of treatment using said nanoparticles and compositions.